Acylin Therapeutics
Acylin Therapeutics operates in the pharmaceutical and drug manufacturing industry developing inhibitors of cellular acetylation.
Launch date
Market cap
-
Enterprise valuation
$8—12m (Dealroom.co estimates Jun 2012.)
Seattle Washington (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
$4.4m | Series A | ||
| N/A | $2.0m | Series A | |
| Total Funding | $6.4m | ||
Related Content
Recent News about Acylin Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.